Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Back ...
In recent days, Ocular Therapeutix highlighted upcoming presentations by its senior scientific and clinical leaders at major ophthalmology meetings, where they discussed evolving treatment approaches ...
Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...
The Korea Research Institute of Standards and Science (KRISS) has developed a retina-mimicking eye phantom that faithfully replicates the structural layers and microvascular network of the human ...
To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...
Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the publication of the results from its Phase 1 ABACUS-1 study of KIO-301 in Nature Medicine. The publication adds clinical detail to a program ...
CRISPR-based gene editing improved vision without serious adverse effects in patients with CEP290-associated inherited retinal degeneration, an interim analysis of a small phase I/II study showed.
Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. A new study may transform ...
The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results